Johnson & Johnson agrees to acquire Ollin Biosciences for up to $3.3 billion to expand retinal disease pipeline

Johnson & Johnson has agreed to acquire ophthalmology biotechnology company Ollin Biosciences for up to approximately $3.3 billion, adding a Phase III retinal disease antibody programme alongside a separate $750 million Blackstone development funding arrangement.
Johnson & Johnson announced on 16 November 2026 that it had entered into a definitive agreement to acquire Ollin Biosciences for $2.2 billion upfront plus up to approximately $1.125 billion in contingent regulatory and commercial milestones, securing access to OLN324, an investigational Phase III bispecific antibody being developed for retinal vascular diseases including wet age-related macular degeneration and diabetic macular oedema.
Under a separate arrangement, Blackstone Life Sciences is expected to contribute $750 million over multiple years towards Phase III development after the acquisition closes, with completion anticipated before the end of 2026 subject to customary conditions; the development financing is distinct from the acquisition consideration, and the full potential transaction value is not guaranteed.
Field | Content |
Article Type | Deals |
Acquirer | Johnson & Johnson |
Target Company | Ollin Biosciences |
Deal Type | Definitive acquisition agreement |
Announcement Date | 16 November 2026 |
Transaction Status | Agreed; closing pending |
Upfront Acquisition Consideration | $2.2 billion |
Potential Contingent Milestones | Up to approximately $1.125 billion |
Maximum Potential Acquisition Consideration | Approximately $3.325 billion |
Rounded Headline Transaction Value | Up to approximately $3.3 billion |
Milestone Categories | Regulatory and commercial |
Milestone Payment Status | Contingent on future achievements |
Principal Acquired Programme | OLN324 |
OLN324 Development Stage | Phase III |
OLN324 Drug Modality | Bispecific antibody |
Therapeutic Area | Ophthalmology |
Disease Focus One | Neovascular age-related macular degeneration |
Disease Focus Two | Diabetic macular oedema |
Related Disease Category | Retinal vascular diseases |
Separate Financing Partner | Blackstone Life Sciences |
Separate Development Funding | $750 million |
Development Funding Purpose | Phase III clinical development |
Development Funding Timing | Over multiple years after acquisition closing |
Financing Included in Acquisition Consideration | No |
Expected Closing | Before the end of 2026 |
Closing Conditions | Subject to customary conditions |
Acquisition Completed | Not at announcement |
OLN324 Regulatory Approval | Not reported |
What Happened | Johnson & Johnson agreed to acquire Ollin Biosciences and its late-stage ophthalmology programme. |
Why It Matters | The transaction expands Johnson & Johnson's retinal disease pipeline with a late-stage investigational bispecific antibody. |
Strategic Significance | Combines acquisition-led pipeline expansion with external development risk-sharing financing. |
Financial Significance | The agreement includes substantial upfront consideration and additional performance-dependent milestone payments. |
Financial Clarification | Blackstone's separate $750 million development funding is not part of the Ollin acquisition purchase price. |
Regulatory Clarification | OLN324 remains investigational and the acquisition does not represent a medicine approval. |
Key Takeaway | Johnson & Johnson plans to acquire Ollin for up to approximately $3.3 billion, with separate Blackstone funding supporting OLN324 development. |
What to Watch | Transaction closing, Phase III clinical progress, regulatory milestones, development funding deployment and future ophthalmology pipeline updates. |
Primary Source | Johnson & Johnson |
Primary Source URL | https://www.jnj.com/media-center/press-releases/johnson-johnson-to-acquire-ollin-biosciences-and-late-stage-bispecific-antibody-with-best-in-class-potential-in-ophthalmology |
Submitted Source | Reuters |
Submitted Source URL | https://www.reuters.com/legal/transactional/jj-strikes-22-billion-buyout-deal-eye-disease-biotech-ollin-biosciences-2026-11-16/ |
Relevant Date | 16 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

Comments